Symphony Financial Services Inc. Purchases 581 Shares of Novo Nordisk A/S (NYSE:NVO)

Symphony Financial Services Inc. lifted its position in Novo Nordisk A/S (NYSE:NVO) by 8.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,399 shares of the company’s stock after purchasing an additional 581 shares during the period. Symphony Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $636,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in NVO. Spinnaker Trust boosted its holdings in shares of Novo Nordisk A/S by 1.1% during the 3rd quarter. Spinnaker Trust now owns 9,615 shares of the company’s stock valued at $1,145,000 after buying an additional 100 shares in the last quarter. Marco Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 1.5% during the 3rd quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock valued at $798,000 after buying an additional 100 shares in the last quarter. Carr Financial Group Corp boosted its holdings in shares of Novo Nordisk A/S by 5.1% during the 3rd quarter. Carr Financial Group Corp now owns 2,100 shares of the company’s stock valued at $250,000 after buying an additional 101 shares in the last quarter. Menard Financial Group LLC boosted its holdings in shares of Novo Nordisk A/S by 0.8% during the 3rd quarter. Menard Financial Group LLC now owns 12,283 shares of the company’s stock valued at $1,463,000 after buying an additional 102 shares in the last quarter. Finally, Optimist Retirement Group LLC boosted its holdings in shares of Novo Nordisk A/S by 4.3% during the 3rd quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company’s stock valued at $327,000 after buying an additional 112 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 2.2 %

Shares of NVO opened at $87.39 on Wednesday. The stock has a market capitalization of $392.17 billion, a price-to-earnings ratio of 26.56, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 1 year low of $77.82 and a 1 year high of $148.15. The business’s 50 day simple moving average is $84.84 and its 200-day simple moving average is $105.85. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is currently 47.72%.

Analysts Set New Price Targets

Several research firms have recently issued reports on NVO. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Finally, BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.